Insulin, Biosimilar and FDA
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in several studies. BIAsp 30 has been shown to be more effective in ...
and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while Tresiba's price will be reduced ...
Find all the commercial and brand names of generic drug called Insulin Aspart. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...
Insulin aspart was the second rapidly acting analogue introduced, approved for clinical use in Europe in 1999 and by the FDA in 2000 for patients with Type 1 or Type 2 diabetes. It is obtained by ...
The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback